section name header

Pronunciation

klor-AM-byoo-sill

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: alkylating agents

Indications

High Alert


Action

  • An alkylating agent that interferes with cellular protein synthesis (cell-cycle phase-nonspecific).
Therapeutic effects:
  • Death of rapidly replicating cells, particularly malignant ones.

Pharmacokinetics

Absorption: Rapidly and completely absorbed from the GI tract.

Distribution: Well distributed to tissues.

Protein Binding: 99%.

Metabolism/Excretion: Extensively metabolized by the liver. Primarily excreted in urine as metabolites.

Half-Life: 1.5 hr.

Time/Action Profile

(effects on WBCs)

ROUTEONSETPEAKDURATION
PO7–14 days7–14 days14–28 days





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: dermatitis, rash

GI: nausea, stomatitis (rare), vomiting

GU: sperm count, sterility

Hemat: anemia, LEUKOPENIA, thrombocytopenia

Metab: hyperuricemia

Resp: pulmonary fibrosis

Misc: allergic reactions, second malignancy

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Leukeran